Skyhawk Therapeutics, Inc. has entered a strategic collaboration with Takeda Pharmaceutical Co. Ltd. under which Skyhawk will use its SkySTAR technology platform to discover and develop small molecule treatments for certain neurological disease targets. The agreement grants Takeda an exclusive worldwide license to develop and commercialize compounds and products directed to multiple targets while Skyhawk receives an upfront payment and is eligible to receive future milestone payments and royalti...